硼替佐米治疗较低危骨髓增生异常综合征患者的探索性临床试验
这项概念验证研究纳入15例骨髓有NF-κB激活证据的较低危MDS患者,皮下注射硼替佐米安全可耐受,3例(20%)获血液学改善(HI-E);13例可评估者中7例(54%,P=0.025)pp65水平下降,10例可评估者中7例(70%)环形铁粒幼红细胞减少。作者认为硼替佐米临床活性有限,蛋白酶体在环形铁粒幼红细胞形成中的作用需进一步研究。
要点
- 皮下硼替佐米在较低危MDS中安全、耐受良好,未见过度毒性。
- 15例中3例(20%)达到血液学改善(HI-E)。
- 13例可评估者中7例(54%)pp65下降(P=0.025),10例可评估者中7例(70%)环形铁粒幼红细胞减少。
核心结论
- 本研究提示以pp65水平衡量的NF-κB激活可能是MDS有用的生物标志物。
- 硼替佐米在该患者人群中安全,但临床活性有限。
- 蛋白酶体在环形铁粒幼红细胞形成中的作用需进一步研究。
研究设计与样本
- 概念验证研究,纳入15例骨髓有NF-κB激活证据的较低危MDS患者,接受皮下硼替佐米治疗。
- 患者中位年龄71岁(范围56-87),按IPSS低危占33%、中危-1占67%,既往治疗中位数为2,全部患者依赖输血。
- 基线中位pp65百分比为31%,11例有环形铁粒幼红细胞证据。
主要发现
- 15例中3例(20%)有血液学改善(HI-E)证据。
- 13例可评估患者中7例(54%)pp65水平下降(P=0.025)。
- 10例可评估患者中7例(70%)治疗期间环形铁粒幼红细胞显著减少。
- 皮下硼替佐米安全、耐受良好,未见过度毒性。
关键数值与推荐
- 15例中3例(20%)达到血液学改善(HI-E)。
- 13例可评估者中7例(54%)pp65水平下降,P=0.025。
- 10例可评估者中7例(70%)环形铁粒幼红细胞减少。
- 基线中位pp65百分比为31%,11例有环形铁粒幼红细胞证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis and an increased risk of transformation. Few effective therapies are available for lower risk MDS patients, especially after the failure of hypomethylating agents. MDS progenitor cells are dependent on the nuclear factor-κB (NF-κB) for survival, which makes it an attractive therapeutic target. As a proteosomal inhibitor, bortezomib is thought to have inhibitory activity against NF-κB. We designed a proof-of-principle study of subcutaneous (SC) bortezomib in lower risk MDS patients with evidence of NF-κB activation in their bone marrow. Fifteen patients were treated, their median age was 71 (range 56-87), 33% were low and 67% int-1 by IPSS, median number of prior therapies was 2, all patients were transfusion dependent. Baseline median pp65 percentage was 31% and 11 patients had evidence of ring sideroblasts (RS). SC bortezomib was safe, well tolerated with no excess toxicity. Three patients out of the 15 (20%) had evidence of response with hematologic improvement (HI-E). Bortezomib caused a decrease in pp65 levels in 7 out of 13 evaluable patients (54%, P = .025). Of interest, unexpectedly, we observed a significant decrease in RS in 7 out of 10 (70%) evaluable patients during treatment. In conclusion, this study suggests that NF-κB activation, measured by pp65 levels, may be a useful biomarker in MDS. Bortezomib is safe in this patient population but has modest clinical activity. The role of the proteasome in the genesis of RS needs further study.
引用
- Daher M, Hidalgo Lopez JE, Randhawa JK, et al. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am J Hematol. 2017. PMID: 28370157. doi:10.1002/ajh.24746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。